Related references
Note: Only part of the references are listed.Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia
Zufei Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016
Shu-Chen Kuo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections
Eilish McCann et al.
INFECTION AND DRUG RESISTANCE (2020)
Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States
Y. P. Tabak et al.
JOURNAL OF HOSPITAL INFECTION (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa
Dandan Yin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers
Cecilia G. Carvalhaes et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection
Makoto Kakara et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2019)
Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)
Uwe Koppe et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2018)
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis
Amber Martin et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa
Kellie J. Goodlet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects
Anthony Aiudi et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2016)
China's national plan to combat antimicrobial resistance
Yonghong Xiao et al.
LANCET INFECTIOUS DISEASES (2016)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Interethnic Differences in Pharmacokinetics of Antibacterials
Danny Tsai et al.
CLINICAL PHARMACOKINETICS (2015)
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Matthew E. Falagas et al.
EMERGING INFECTIOUS DISEASES (2014)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies
S. U. Yasuda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs
SE Cosgrove
CLINICAL INFECTIOUS DISEASES (2006)
Share Paper
